Stoke Therapeutics (STOK) Institutional Ownership

Of the 149 institutional investors that purchased Stoke Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Toronto Dominion Bank ($6.35M), Lynx1 Capital Management LP ($2.23M), Assenagon Asset Management S.A. ($2.20M), RTW Investments LP ($1.32M), Corient Private Wealth LLC ($1.32M), State Street Corp ($1.21M), and Marshall Wace LLP ($1.15M).

Institutional investors have bought a total of 12,658,253 shares in the last 24 months. This purchase volume represents approximately $320.24M in transactions.

Of the 48 institutional investors that sold Stoke Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Skorpios Trust ($4.65M), Marshall Wace LLP ($1.53M), Baker BROS. Advisors LP ($1.30M), Royal Bank of Canada ($914.16K), Assenagon Asset Management S.A. ($742.34K), Granahan Investment Management LLC ($341.02K), and Bank of America Corp DE ($298.64K).

Institutional investors have sold a total of 11,001,001 shares in the last 24 months. This volume of shares sold represents approximately $235.70M in transactions.